Last reviewed · How we verify
NCT05681598
Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
NA trial testing Hydroxyurea in Sickle-Cell Anaemia in 166 participants. Completed in 16 May 2020.
16 May 2020
Quick facts
| Lead sponsor | University of Kinshasa |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 166 |
| Start date | 30 August 2017 |
| Primary completion | 16 May 2020 |
| Estimated completion | 16 May 2020 |
| Sites | 1 location across Democratic Republic of the Congo |
Drugs / interventions tested
- Hydroxyurea — full drug profile →
Conditions studied
- Sickle-Cell Anaemia — all drugs for Sickle-Cell Anaemia →
Sponsor
University of Kinshasa
Who can join
Adults 18 to 40, any sex, with Sickle-Cell Anaemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy of hydroxyurea (HU) in improving disease severity in adult patients with sickle cell anemia in Kinshasa (Democratic Republic of Congo). This study aims to: * assess the safety and efficacy of HU treatment in the Congolese environment; * assess the reversibility of chronic cardiac lesions. Participants will take hydroxyurea for two years. The effects of the treatment will be evaluated periodically by clinical evaluation, biological tests, and echocardiographic exploration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05681598
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydroxyurea
Trials testing the same drug.
- NCT06930352 — Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for S · Phase 2 · not yet recruiting
- NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT06526117 — Stroke Prevention in Nigeria 2 Trial · Phase 4 · recruiting
- NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
- NCT05285917 — Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa · Phase 3 · recruiting
Other University of Kinshasa trials
Trials by the same sponsor.
- NCT04783051 — Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) · Phase 3 · completed
- NCT04424940 — COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach · unknown
- NCT07355426 — Clinical Prediction Models for Pediatric In-Hospital Death Risk in Congolese Severe Malaria Children Using Machine Learn · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05681598 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kinshasa
- Last refreshed: 12 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05681598.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing